TrialsgrambetaRCTs are beautiful

Kidney transplantation

Immunosuppression regimens, belatacept, mTOR conversion and HCV-positive donors.

Trials
6
Years
2007–2024
Sort
  • 2024Felzartamab AMR⁠Antibody-mediated rejectionIn 22 kidney-transplant recipients with chronic active antibody-mediated rejection, felzartamab resolved rejection morphology more often than placebo.82% vs 20%Read →
  • 2018TRANSFORM⁠mTOR inhibitorsIn 2,037 de-novo kidney-transplant recipients, everolimus with reduced calcineurin inhibitor was non-inferior for rejection, graft loss or death compared with mycophenolate with standard calcineurin inhibitor.48.2% vs 45.1%Read →
  • 2017THINKER⁠HCV-positive donorsIn 20 HCV-negative recipients of hepatitis-C-viraemic donor kidneys, antiviral therapy achieved a sustained virologic response in every patient.Read →
  • 2016BENEFIT⁠BelataceptIn 666 kidney-transplant recipients, belatacept improved 7-year patient and graft survival compared with ciclosporin.HR 0.5795% CI 0.35-0.95Read →
  • 2011ZEUS 2011⁠mTOR inhibitorsIn 300 kidney-transplant recipients, early conversion from ciclosporin to everolimus improved kidney function compared with continued ciclosporin.Read →
  • 2007ELITE-Symphony Core⁠ImmunosuppressionIn 1,645 kidney-transplant recipients, low-dose tacrolimus with mycophenolate and steroids gave better graft function than the other immunosuppressive regimens.Read →